Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation
The use of granulocyte colony stimulating factor (G-CSF) biosimilars for peripheral blood hematopoietic stem cell (PBSC) mobilization has stimulated an ongoing debate regarding their efficacy and safety. However, the use of biosimilar G-CSF was approved by the European Medicines Agency (EMA) for all...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2014.01.23
|
| In: |
Theranostics
Year: 2014, Volume: 4, Issue: 3, Pages: 280-289 |
| ISSN: | 1838-7640 |
| DOI: | 10.7150/thno.7752 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.7150/thno.7752 Verlag, lizenzpflichtig, Volltext: http://www.thno.org/v04p0280.htm |
| Author Notes: | Michael Schmitt, Amy Publicover, Kim H Orchard, Matthias Görlach, Lei Wang, Anita Schmitt, Jiju Mani, Panagiotis Tsirigotis, Reeba Kuriakose, Arnon Nagler |
| Summary: | The use of granulocyte colony stimulating factor (G-CSF) biosimilars for peripheral blood hematopoietic stem cell (PBSC) mobilization has stimulated an ongoing debate regarding their efficacy and safety. However, the use of biosimilar G-CSF was approved by the European Medicines Agency (EMA) for all the registered indications of the originator G-CSF (Neupogen®) including mobilization of stem cells. Here, we performed a comprehensive review of published reports on the use of biosimilar G-CSF covering patients with hematological malignancies as well as healthy donors that underwent stem cell mobilization at multiple centers using site-specific non-randomized regimens with a biosimilar G-CSF in the autologous and allogeneic setting. |
|---|---|
| Item Description: | Gesehen am 27.10.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1838-7640 |
| DOI: | 10.7150/thno.7752 |